misonidazole has been researched along with niacinamide in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Varnes, ME | 1 |
| Dische, S; Hoskin, PJ; Saunders, MI | 1 |
| Droller, MJ | 1 |
| Glaholm, J; Watkinson, JC | 1 |
| Ando, K; Hirayama, R; Kashino, G; Kinashi, Y; Koike, S; Liu, Y; Masunaga, S; Ono, K; Suzuki, M; Takata, T; Tanaka, H; Uzawa, A | 1 |
| Chowdhury, NF; Kuge, Y; Murakami, M; Nishijima, K; Takiguchi, M; Tamaki, N; Yu, W; Zhao, S; Zhao, Y | 1 |
| Hoskin, P; Tharmalingham, H | 1 |
1 review(s) available for misonidazole and niacinamide
| Article | Year |
|---|---|
Clinical trials targeting hypoxia.
Topics: Animals; Cell Hypoxia; Female; Humans; Male; Misonidazole; Neoplasms; Niacinamide; Oxygen Consumption; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Tumor Hypoxia | 2019 |
1 trial(s) available for misonidazole and niacinamide
| Article | Year |
|---|---|
Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide.
Topics: Adult; Aged; Carbon Dioxide; Humans; Hyperbaric Oxygenation; Middle Aged; Misonidazole; Niacinamide; Oxygen; Radiation-Sensitizing Agents; Radiotherapy Dosage; Urinary Bladder Neoplasms | 1999 |
5 other study(ies) available for misonidazole and niacinamide
| Article | Year |
|---|---|
Inhibition of pentose cycle of A549 cells by 6-aminonicotinamide: consequences for aerobic and hypoxic radiation response and for radiosensitizer action.
Topics: 6-Aminonicotinamide; Anaerobiosis; Humans; Misonidazole; NADP; Niacinamide; Oxygen; Pentose Phosphate Pathway; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1988 |
Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen and nicotinamide.
Topics: Carbon Dioxide; Humans; Hyperbaric Oxygenation; Misonidazole; Niacinamide; Oxygen; Radiation-Sensitizing Agents; Urinary Bladder Neoplasms | 2000 |
Developments in radiotherapy and adjuvant chemotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Cell Hypoxia; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose Fractionation, Radiation; Etanidazole; Head and Neck Neoplasms; Humans; Misonidazole; Niacinamide; Vasodilator Agents | 2003 |
Influence of manipulating hypoxia in solid tumors on the radiation dose-rate effect in vivo, with reference to that in the quiescent cell population.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Carbon Radioisotopes; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Radiation; Female; Fluorescent Antibody Technique; Gamma Rays; Mice; Mice, Inbred C3H; Misonidazole; Niacinamide; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Vitamin B Complex | 2010 |
Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Humans; Hypoxia; Kidney Neoplasms; Mice; Mice, Nude; Misonidazole; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Radiopharmaceuticals; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |